These data provided new evidence for the mechanism by which abundant p62 expression promoted ICC progression, suggesting a promising therapeutic target for antimetastatic strategies in patients with ICC. This evidence concerns the gene SQSTM1 and intrahepatic cholangiocarcinoma.